4.7 Article

Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality

期刊

出版社

AMER MEDICAL ASSOC
DOI: 10.1001/jama.2010.1237

关键词

-

资金

  1. Public Health Service [R01-CA83855, R01-CA102776, NO1-CN-6700]
  2. University of Pennsylvania Cancer Center
  3. Cancer Genetics Network [HHSN21620074400C]
  4. Marjorie Cohen Research Fund
  5. Dana-Farber/Harvard Cancer Center [BC P50 CA-089393]
  6. US Department of Defense [DAMD-17-96-I-6088, DAMD-17-94-J-4340, DAMD-17-97-I-7112, DAMD-17-03-I-0619]
  7. Utah State Department of Health
  8. Nebraska State Cancer and Smoking-Related Diseases Research [LB595, P30-CA-16042]
  9. Cancer Research UK [C5047/A7357]
  10. National Cancer Institute [P30 CA51008-12]
  11. Doris Duke Distinguished Clinical Scientist
  12. National Institute for Health Research
  13. [P30-CA51008-15]

向作者/读者索取更多资源

Context Mastectomy and salpingo-oophorectomy are widely used by carriers of BRCA1 or BRCA2 mutations to reduce their risks of breast and ovarian cancer. Objective To estimate risk and mortality reduction stratified by mutation and prior cancer status. Design, Setting, and Participants Prospective, multicenter cohort study of 2482 women with BRCA1 or BRCA2 mutations ascertained between 1974 and 2008. The study was conducted at 22 clinical and research genetics centers in Europe and North America to assess the relationship of risk-reducing mastectomy or salpingo-oophorectomy with cancer outcomes. The women were followed up until the end of 2009. Main Outcomes Measures Breast and ovarian cancer risk, cancer-specific mortality, and overall mortality. Results No breast cancers were diagnosed in the 247 women with risk-reducing mastectomy compared with 98 women of 1372 diagnosed with breast cancer who did not have risk-reducing mastectomy. Compared with women who did not undergo risk-reducing salpingo-oophorectomy, womenwho underwent salpingo-oophorectomy had a lower risk of ovarian cancer, including those with prior breast cancer (6% vs 1%, respectively; hazard ratio [HR], 0.14; 95% confidence interval [CI], 0.04-0.59) and those without prior breast cancer (6% vs 2%; HR, 0.28 [95% CI, 0.12-0.69]), and a lower risk of first diagnosis of breast cancer in BRCA1 mutation carriers (20% vs 14%; HR, 0.63 [95% CI, 0.41-0.96]) and BRCA2 mutation carriers (23% vs 7%; HR, 0.36 [95% CI, 0.16-0.82]). Compared with women who did not undergo risk-reducing salpingo-oophorectomy, undergoing salpingo-oophorectomy was associated with lower all-cause mortality (10% vs 3%; HR, 0.40 [95% CI, 0.26-0.61]), breast cancerspecific mortality (6% vs 2%; HR, 0.44 [95% CI, 0.26-0.76]), and ovarian cancerspecific mortality (3% vs 0.4%; HR, 0.21 [95% CI, 0.06-0.80]). Conclusions Among a cohort of women with BRCA1 and BRCA2 mutations, the use of risk-reducing mastectomy was associated with a lower risk of breast cancer; risk-reducing salpingo-oophorectomy was associated with a lower risk of ovarian cancer, first diagnosis of breast cancer, all-cause mortality, breast cancer-specific mortality, and ovarian cancer-specific mortality. JAMA. 2010; 304(9): 967-975 www.jama.com

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据